Walleye Capital
AMLX icon

Walleye Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Walleye Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Buy
6,600
+4,800
+267% +$74.2K ﹤0.01% 3802
2026
Q1 		$25K Sell
1,800
-7,100
-80% -$99.9K ﹤0.01% 4042
2025
Q4 		$108K Buy
8,900
+2,100
+31% +$28.5K ﹤0.01% 3841
2025
Q3 		$92.4K Buy
+6,800
New +$64K ﹤0.01% 3739
2025
Q1 		– Sell
-33,500
Closed -$127K – 4205
2024
Q4 		$127K Buy
+33,500
New +$158K ﹤0.01% 4019
2024
Q2 		– Sell
-100
Closed -$284 – 5548
2024
Q1 		$284 Buy
+100
New +$1.31K ﹤0.01% 5348
2023
Q4 		– Sell
-1,800
Closed -$33K – 4901
2023
Q3 		$33K Buy
+1,800
New +$38.1K ﹤0.01% 4295
2023
Q1 		– Sell
-6,700
Closed -$248K – 3898
2022
Q4 		$248K Buy
+6,700
New +$238K ﹤0.01% 1908

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Walleye Capital's AMLX Position: Q2 2026 in Review

Walleye Capital increased its Amylyx Pharmaceuticals (AMLX) stake by 202% in Q2 2026, buying an estimated $1.93M and bringing the position to 186,588 shares worth $3.35M. The position accounts for 0.01% of the portfolio, ranked #1094.

Walleye Capital first reported a position in AMLX in Q1 2022 and has held it in 14 quarters since. The position peaked at $8.58M in Q4 2023. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Walleye Capital held 186,588 shares of Amylyx Pharmaceuticals worth $3.35M as of Q2 2026.
  • Walleye Capital bought 124,877 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.93M.
  • Amylyx Pharmaceuticals made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1094 holding.
  • Walleye Capital first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
  • Walleye Capital's Amylyx Pharmaceuticals position peaked at $8.58M in Q4 2023.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.